Journal of Cancer Clinical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-7360-538437

Mini Review - Journal of Cancer Clinical Research (2022) Volume 5, Issue 4

Neoadjuvant therapy pancreatic cancer& breast cancer meta-analysis of randomized controlled trials

Neoadjuvant chemotherapy is commonly given to patients with non metastatic breast cancer to de-escalate the degree of surgery within the breast and axilla. Tumor science significantly impacts the probability of accomplishing a pathologic total reaction, which has both prognostic and helpful implications. Ongoing clinical trials are evaluating both acceleration and de-escalation of surgery, radiation treatment, and adjuvant systemic treatment based on tumor reaction to neoadjuvant chemotherapy. Neoadjuvant treatment may move forward survival compared with forthright surgery in patients with resectable and borderline resectable pancreatic cancer, but high-quality prove is lacking. We methodicallly looked for randomized trials comparing neoadjuvant treatment with forthright surgery for resectable and borderline resectable pancreatic cancer distributed since database beginning until December 2020. The essential result was in general survival by intention-to-treat with subgroup examinations for resectability

Author(s): Melissa Ferraro

Abstract Full Text PDF

Get the App